A New Paradigm in Mechanical Circulatory Support: 100-Patient Experience

Area of Science:

• Cardiology
• Medical Devices
• Mechanical Circulatory Support

Background:

• Acutely decompensated heart failure (ADHF) poses significant clinical challenges.
• Existing temporary support measures for ADHF often carry substantial adverse effects.
• The Impella 5.0, a minimally invasive temporary left ventricular assist device (LVAD), has been developed to address these limitations.

Purpose of the Study:

• To evaluate the safety and efficacy of the Impella 5.0 LVAD in patients with ADHF.
• To assess outcomes based on the intended support strategy: bridge to recovery (BTR), bridge to durable device (BTDD), or bridge to transplantation (BTT).

Main Methods:

• A retrospective analysis of 100 patients with ADHF treated with an axillary Impella 5.0 LVAD from January 2014 to September 2018.
• Patients were categorized into BTR, BTDD, or BTT groups.
• Demographic data, baseline characteristics, and survival outcomes were compared across groups.

Main Results:

• The study included 100 patients (84% male, average age 56.7 years) with severely reduced ejection fraction (average 16%) and advanced INTERMACS profiles.
• Overall survival was 64%, with significantly higher survival in the BTT group (81%) compared to BTR (50%) and BTDD (48%) groups (P = .007).
• Survival improved over the study period, with 90% survival in the most recent 30 patients.

Conclusions:

• The Impella 5.0 LVAD is a viable and attractive option for supporting ADHF patients.
• This minimally invasive device facilitates support for patients aiming for recovery, durable LVAD, or heart transplantation.
• Outcomes suggest a positive trend in survival with accumulating experience using the Impella 5.0 for ADHF management.